| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Stephen T. Holgate | Q1547900 |
| P2093 | author name string | Bacon A | |
| Church MK | |||
| Anderson DF | |||
| McGill JI | |||
| P2860 | cites work | A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I | Q73281048 |
| Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis | Q73708247 | ||
| The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma | Q73863296 | ||
| Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis | Q74388708 | ||
| A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group | Q74424008 | ||
| Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration | Q74810209 | ||
| [Studies on allergic conjunctivitis. 13. Effects of neonatally injected androgen on experimental allergic conjunctivitis] | Q93709767 | ||
| Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1 | Q24562120 | ||
| TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties | Q29547848 | ||
| Cytological and immunohistochemical study of the limbal form of vernal keratoconjunctivitis by the replica technique | Q33645994 | ||
| Prevalence of asthma and hay fever in England and Wales | Q34068397 | ||
| Conjunctival eosinophils in allergic ocular disease | Q34713580 | ||
| Demand incidence and episode rates of ophthalmic disease in a defined urban population | Q35824196 | ||
| Prevalence of asthma in adults in Busselton, Western Australia | Q35824635 | ||
| Inhalation challenge with specific grass pollen antigens in asthmatics and the effect of lodoxamide tromethamine | Q36129114 | ||
| Allergic ocular disorders: a spectrum of diseases | Q36215890 | ||
| Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis | Q36650757 | ||
| Changing prevalence of asthma in Australian children | Q36885947 | ||
| Hayfever in the United Kingdom | Q36928555 | ||
| A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis | Q37306385 | ||
| Eosinophils and T-lymphocytes in late-phase allergic reactions | Q37906619 | ||
| Effects of gender and sex steroids on the immune response | Q38147161 | ||
| H1-receptor antagonists: clinical pharmacology and therapeutics | Q38369357 | ||
| Diagnosis of allergic conjunctivitis | Q38583138 | ||
| Prevalence of atopic disorders among adolescents in Turku, Finland | Q39235560 | ||
| Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis | Q39485261 | ||
| Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis | Q39490863 | ||
| Ocular allergy and mast cell stabilizers | Q39587818 | ||
| Ocular allergy | Q39633182 | ||
| Epidemiology of hay fever and perennial allergic rhinitis | Q39680599 | ||
| Contact allergic dermatitis and contact urticaria due to topical ophthalmic preparations | Q39697252 | ||
| Studies on allergic conjunctivitis. 10. Effects of neonatally injected estrogen on experimental allergic conjunctivitis | Q71561411 | ||
| Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases | Q71563676 | ||
| IgG specific antibodies to rye grass and ragweed pollen antigens in the tear secretions of patients with vernal conjunctivitis | Q71658061 | ||
| Multiple cytokine mRNA expression in human mast cells stimulated via Fc epsilon RI | Q71701576 | ||
| Group comparative trial of 2% nedocromil sodium with placebo in the treatment of seasonal allergic conjunctivitis | Q72032774 | ||
| Vernal keratopathy and its management | Q72069830 | ||
| Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis | Q72226404 | ||
| The origin of keratopathy in chronic allergic eye disease: a histopathological study | Q72638258 | ||
| Nedocromil sodium in contact-lens-associated papillary conjunctivitis | Q72638263 | ||
| Complement activation requirements for histamine release from human leukocytes: influence of purified C3ahu and C5ahu on histamine release | Q72649758 | ||
| Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies | Q72675185 | ||
| Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis | Q72691302 | ||
| Intraocular pressure response to loteprednol etabonate in known steroid responders | Q72866271 | ||
| Nedocromil sodium and astemizole, alone or combined, in the treatment of seasonal allergic conjunctivitis. A multicentre double blind clinical trial | Q72965810 | ||
| A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis | Q72992644 | ||
| Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity | Q73133579 | ||
| Management of allergic conjunctivitis | Q73180126 | ||
| Immunoglobulins: structure, function and relation to the eye. | Q39878751 | ||
| Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy | Q40618541 | ||
| Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva | Q40643634 | ||
| The role of the mast cell in acute and chronic allergic inflammation. | Q40671452 | ||
| Conjunctivitis of allergic origin: clinical presentation and differential diagnosis | Q40778106 | ||
| Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis | Q40812592 | ||
| The biology of the eosinophilic leukocyte | Q40898065 | ||
| Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease | Q40929445 | ||
| ANTIBODIES TO GRASS IN VERNAL CONJUNCTIVITIS. | Q40980246 | ||
| Role of Staphylococcus aureus in chronic allergic conjunctivitis. | Q41114535 | ||
| Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia | Q41115387 | ||
| Interleukin-4 and its receptor: essential mediators of the allergic response | Q41324417 | ||
| Inhibition by nedocromil sodium of IgE-mediated activation of human mononuclear phagocytes and platelets in allergy. | Q41333595 | ||
| Degranulatory action of estradiol on blood eosinophil leukocytes in vivo and in vitro | Q41508230 | ||
| Human skin mast cells: their dispersion, purification, and secretory characterization | Q41790980 | ||
| Eye disease at a community health centre | Q41878874 | ||
| Adhesion molecules and relationship to leukocyte levels in allergic eye disease | Q42451282 | ||
| Effects of interleukins on connective tissue type mast cells co-cultured with fibroblasts | Q42475996 | ||
| Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells | Q42545586 | ||
| Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate | Q42563619 | ||
| Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from mast cells from various locations | Q43557830 | ||
| Limbal vernal keratoconjunctivitis: clinical characteristics and immunoglobulin E expression compared with palpebral vernal | Q43635189 | ||
| Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis | Q44969608 | ||
| Mast cell numbers and staining characteristics in the normal and allergic human conjunctiva | Q50876279 | ||
| Non-IgE-dependent bacteria-induced histamine release from human lung and tonsillar mast cells. | Q54764028 | ||
| Effects of nedocromil sodium (Tilade®) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells | Q55094071 | ||
| Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation | Q59685320 | ||
| Efficacy of Lodoxamide Eye Drops on Mast Cells and Eosinophils after Allergen Challenge in Allergic Conjunctivitis | Q61685030 | ||
| Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis | Q61685068 | ||
| Atopic keratoconjunctivitis | Q62116814 | ||
| Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis | Q64987580 | ||
| Number of inflammatory cells in the normal conjunctiva | Q67374173 | ||
| Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis | Q67507903 | ||
| Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine | Q67535901 | ||
| Giant papillary conjunctivitis in contact lens wearers | Q67582469 | ||
| Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study | Q67592853 | ||
| Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen | Q67657662 | ||
| Mast cell hyperplasia in atopic keratoconjunctivitis. An immunohistochemical study | Q67872022 | ||
| Topical Cyclosporine in Vernal Keratoconjunctivitis | Q67873050 | ||
| The c-kit receptor ligand functions as a mast cell chemoattractant | Q67895085 | ||
| Levocabastine. Evaluation in the histamine and compound 48/80 models of ocular allergy in humans | Q68005375 | ||
| Immunopathology of atopic keratoconjunctivitis | Q68018590 | ||
| Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis | Q68330941 | ||
| Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis | Q68697088 | ||
| Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis | Q68746689 | ||
| The cellular response of the human allergic mucosa to natural allergen exposure | Q69049307 | ||
| Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis | Q69661913 | ||
| Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test | Q69897986 | ||
| The effect of levocabastine nasal spray in nasal provocation tests | Q69917499 | ||
| Clinical features of atopic keratoconjunctivitis | Q70125167 | ||
| Stimulation of IgE sensitized human alveolar macrophages by anti-IgE is unaffected by sodium cromoglycate | Q70315532 | ||
| Mast cell ultrastructure. Comparison in contact lens-associated giant papillary conjunctivitis and vernal conjunctivitis | Q70863621 | ||
| Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis | Q71225091 | ||
| Ocular complications of atopic dermatitis | Q71321487 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 1203-1214 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Allergic eye disease mechanisms | |
| P478 | volume | 82 |
| Q36104875 | A review of the use of olopatadine in allergic conjunctivitis |
| Q39628123 | Allergic Conjunctivitis and the Associated Risk of Migraine Among Children: A Nationwide Population-based Cohort Study |
| Q84135372 | Allergic conjunctivitis and nasal allergy |
| Q52842401 | Allergy, Histamine and Antihistamines. |
| Q30877898 | Atopy: a patient-specific risk factor for diffuse lamellar keratitis |
| Q34039956 | Conjunctival cytokines in ocular allergy |
| Q48157666 | Decreased viability and proliferation of CHANG conjunctival epithelial cells after contact with ultraviolet light-irradiated pollen. |
| Q36219638 | Emerging drugs for ocular allergy |
| Q41852217 | Human conjunctival epithelial cell responses to platelet-activating factor (PAF): signal transduction and release of proinflammatory cytokines |
| Q33770917 | Hydrocortisone concentration influences time to clinically significant healing of acute inflammation of the ocular surface and adnexa - results from a double-blind randomized controlled trial |
| Q73840341 | Increase in CD45RO+ cells and activated eosinophils in chronic allergic conjunctivitis |
| Q34533774 | Inhibitory effects of ketotifen on eotaxin‐dependent activation of eosinophils: consequences for allergic eye diseases |
| Q37074387 | Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis |
| Q24188328 | Mast cell stabilisers for seasonal and perennial allergic conjunctivitis |
| Q24202609 | Mast cell stabilisers for seasonal and perennial allergic conjunctivitis |
| Q41131580 | Nasal-ocular reflexes and their role in the management of allergic rhinoconjunctivitis with intranasal steroids |
| Q33735876 | Quantification of tear proteins and sPLA2-IIa alteration in patients with allergic conjunctivitis |
| Q35761720 | Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. |
| Q35187578 | Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis |
| Q36712942 | The Dundee University Scottish Keratoconus study: demographics, corneal signs, associated diseases, and eye rubbing |
| Q37140688 | The dendritic cell in allergic conjunctivitis. |
| Q82619639 | The possible involvement of nasal allergy in allergic keratoconjunctivitis |
| Q37037418 | Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders |
| Q34620159 | Updates in the treatment of ocular allergies |
| Q48201733 | Vernal keratoconjunctivitis: culmination of management using immunosuppression, surgical and prosthetic therapy over quarter century |
| Q81354643 | [Implantation of preserved human amniotic membrane for the treatment of shield ulcers and persistent corneal epithelial defects in chronic allergic keratoconjunctivitis] |
| Q81606847 | [Ocular allergies] |
Search more.